MENU
Go to the list of all blogs
Vitalii Liubimov's Avatar
published in Blogs
Jul 28, 2020

It’s Big Pharma’s Turn in the Earnings Confessional

Many of the top pharmaceutical companies are working on a vaccination for COVID-19. It seems as if new trial results are released on a daily basis for one drug or another. The global pandemic has certainly changed the fortunes for a number of companies and the attention is obviously warranted.

We don’t have a vaccine yet and there is definitely a race on between big pharma companies to produce a viable vaccine. In the meantime, it seems as if the earnings reports of the companies have taken a backseat to the vaccine research. That may change this week as several major pharmaceutical companies will report earnings on Thursday and Friday.

AstraZeneca (AZN) and Eli Lilly (LLY) are both set to report earnings on Thursday, July 30. Merck (MRK) is set to report on Friday, July 31.

Looking at the Tickeron scorecard, Eli Lilly is rated as a “strong buy” and Astrazeneca is rated as a “buy”. Merck doesn’t fare as well and is rated as a “sell”. The major pharmaceutical industry as a whole is rated as a “sell” so these three are above average as a group. Looking at the price change of these three stocks over the past year we see that Merck has not performed well compared to Lilly and Astrazeneca. Lilly is up over 50% and Astrazeneca is up almost 34%. Merck is down ever so slightly over the last 12 months.

We see that Lilly does extremely well with its fundamental ratings with five positive readings and not a single negative one. Astrazeneca does almost as well with four positive readings and one negative reading. We see the summary below and it includes all of the positive ratings for Astra. The two that aren’t shown for Lilly are its outlook and its seasonality score.

Merck doesn’t do terribly on its fundamental ratings. It has three positive ratings and one negative rating. The negative one is pretty high at 73 and that’s the P/E Growth Rating.

I took note of the fact that all three stocks are considered undervalued at this time and all three have really low scores—single-digit low. The Profit Vs. Risk Rating and the SMR Rating for Lilly are also really low and in the single digits. That helps explain why the stock gets a “strong buy” rating.

Turning our attention to the technical analysis ratings, Astra actually scores a little better than Lilly and Merck doesn’t fare as well once again. Astra gets positive ratings in the MACD, Momentum, and Moving Average categories with negative ratings from the Bollinger Bands and the RSI.

Lilly gets positive ratings from the AROON Indicator and from the Bollinger Bands and it gets negative ratings from the RSI and the Momentum Indicator. Merck’s only positive rating is from the Momentum Indicator and it doesn’t get any negative ratings at this time.

If you look at the weekly charts of the three stocks, Astra was in overbought territory based on a 10-week RSI and the weekly stochastic indicators, but a decline last week moved the stock below overbought levels. Lilly was also overbought based on the weekly stochastic readings, but the RSI hasn’t been in overbought territory since February. With Merck lagging the other two and the overall market, its oscillators are down around the middle of the range at this time. Merck has been grinding sideways between $75 and $82.50 since March.

Heading in to the earnings reports, Astra and Lilly have seen small reductions in the EPS estimate over the last three months while Merck’s estimate has dropped more significantly. Astra and Lilly are both expected to see earnings grow compared to the second quarter of 2019, but Merck is expected to see earnings decline by 20%.

One of the more interesting things I found when looking at the sentiment was that Merck had the highest buy percentage from analysts. Of the 18 analysts covering the stock, 13 gave the stock a “buy” rating with five “hold” ratings. This gives us a buy percentage of 72.2%. Astra’s buy percentage is 66.7% and Lilly’s is 53.3%.

None of the three short interest ratios (SIR) are very high, but Astra’s is really low at only 0.2. While this isn’t necessarily a negative for the stock, it just means that a short covering rally isn’t in the works.

Looking at all of the data from all three analysis styles, I am in complete agreement with the Tickeron Scorecard. Lilly looks the best of the three for the long-term and I would also consider it a strong buy. Astrazeneca looks good as well and I think a buy rating is accurate. Merck just doesn’t look all that great right now and probably deserves a sell rating or a hold rating at best.

Related Ticker: AZN

AZN in downward trend: price dove below 50-day moving average on April 01, 2025

AZN moved below its 50-day moving average on April 01, 2025 date and that indicates a change from an upward trend to a downward trend. In of 58 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for AZN moved out of overbought territory on March 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on March 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on AZN as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for AZN turned negative on March 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in of 352 cases, the price rose further within the following month. The odds of a continued upward trend are .

AZN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 276 cases where AZN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.325) is normal, around the industry mean (5.632). P/E Ratio (35.297) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.870) is also within normal values, averaging (3.004). Dividend Yield (0.022) settles around the average of (0.161) among similar stocks. P/S Ratio (4.585) is also within normal values, averaging (3.643).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 86.34B. The market cap for tickers in the group ranges from 72.83K to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -2%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was -7%. CSPCY experienced the highest price growth at 17%, while LYPHF experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 6%. For the same stocks of the Industry, the average monthly volume growth was -19% and the average quarterly volume growth was 79%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 32
P/E Growth Rating: 63
Price Growth Rating: 54
SMR Rating: 61
Profit Risk Rating: 74
Seasonality Score: 17 (-100 ... +100)
View a ticker or compare two or three
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1 Francis Crick Avenue
Phone
+44 2037495000
Employees
89900
Web
https://www.astrazeneca.com
Ad is loading...
"🚀 PHAXIAM Therapeutics SA Skyrockets +18.82%! Dive into this biotech penny stock's stellar week and the industry's broader movements. 📈🔬
Explore annualized returns of +110% for Day Traders and +50% for Swing Traders using Price Action Trading Strategies (TA&FA) on popular managed healthcare stocks like $BIOS $CI $CNC $ELV $HUM $MOH $UNH. Stay updated on the 1-week change of +3% in this dynamic market.
The ethanol industry encompasses a diverse range of business activities, primarily focusing on the production of ethanol and sugar. Beyond these core products, companies within this theme also engage in the development of related assets, such as fuel storage tanks.
Cisco Systems set to soar! 🚀 A.I. predicts +4% growth in the coming month. Is CSCO the next big move in your portfolio? 📈💰
#trading
The Office Equipment/Supplies sector has emerged as a standout performer in recent times, posting an impressive 6.13% increase in its performance over the past week. This surge in performance is supported by a group of tickers, including $ACTG, $SCS, $HNI, $EBF, and $ACCO, which have collectively displayed a positive outlook. In this article, we will delve into the theme of this sector and analyze the group of tickers within it that are driving this positive momentum.
"IBM Skyrockets: +15.54% Quarterly Jump! Dive into the data behind this tech titan's remarkable rally. 📈🚀"
#investment#trading
The pharmaceutical sector is known for its dynamic nature, with companies often experiencing rapid shifts in performance and sentiment. In the past week, pharmaceutical companies, as represented by a group of tickers including RPRX, CALT, INZY, and HRMY, have seen a noteworthy increase in performance, surging by +3.13%. In this article, we will delve into the details of this trend, explore key indicators, and assess the outlook for these companies.
The term 'challenging disorders' envelops a vast expanse of the healthcare sector, extending from medical devices, facilities to biotechs, and pharmaceutical firms.
The ocean transportation sector has been making waves recently, experiencing a significant performance boost of +3.74% over the past week. In this article, we'll delve into the theme and explore the key tickers within this sector, shedding light on their market capitalization, recent price movements, volume trends, and fundamental analysis ratings.
Forest products encompass materials harvested from forestry intended for direct utilization or commercial activities.
The toy industry has seen some significant ups and downs in recent times, with a cluster of notable companies taking center stage in this exciting and ever-evolving market. In this article, we delve into the recent performance of select toy companies, examining key indicators and trends that have shaped their stock movements.
Dive into the dynamics behind the recent 2.68% rise in the Wholesale Distributors sector. With standout performers like $GIC, $POOL, $SITE, $FERG, and $CNM, we dissect the market movements and pivotal factors driving this uptrend. Read on to stay ahead!
🚀 Biocept (BIOC) surges +51.63% in a month! Amid industry downtrends, BIOC shines. What's next for this penny stock? 📈
#latest#investment
The aluminum construction companies have experienced a significant boost, with the segment seeing a +11.13% increase in performance over the past week. This growth is largely driven by the rising demand for lightweight materials, particularly in the automotive sector, where aluminum is being widely adopted to improve fuel efficiency. The aluminum industry plays a vital role in the U.S. economy, generating approximately $71 billion annually in direct economic impact, according to The Aluminum Association.
Unlock the potential of AI-powered swing trading with robots designed to track dips in top S&P 500 stocks. Whether you're a beginner or experienced trader, these tools help manage up to $20k per position, balancing risk and reward with advanced algorithms and market insights. Discover how to maximize returns in volatile markets!
Discover Tickeron's new AI-driven trading bots designed for high-volatility markets and impulse price action. Leveraging Financial Learning Models (FLMs) and technical analysis, these bots optimize trades, offer a 70% win rate, and execute strategies for day traders focused on fast market moves.
The Diesel Companies segment has displayed a notable increase of +9.44% in performance over the past week. This uptick highlights a positive trend in the sector, encompassing companies involved in the manufacturing of diesel vehicles and the distribution of transportation fuels.
The medical companies segment has experienced a notable increase in performance, recording a weekly gain of +3.53%. This sector encompasses companies involved in the production and supply of pharmaceuticals and essential medical products, catering to a broad spectrum of healthcare needs. Their product offerings include surgical apparel, gloves, hospital furniture, fluid management solutions, and specialized equipment for cosmetic and surgical procedures.
Tickeron launches AI-powered Stock Picker robots to assist hedge fund managers with sector rotation, growth-focused small-cap stocks, and strategic risk management. Using proprietary FLMs, Stock Pickers offer quant-driven signals and adaptive strategies for long-term growth and investment
Tickeron unveils an intuitive AI trading bot interface, offering tailored strategies for day, swing, and trend traders. From beginners to pros, discover tools designed to optimize trading precision, adapt to market volatility, and provide hedge fund-level insights for smarter investments.
#latest#popular#trading